Physician critiques new Alzheimer's drug approval

01. lokakuuta 2025 Raportoinut AI

In an opinion piece published on MedPage Today, oncologist Vinay Prasad argues that the FDA's approval of lecanemab for Alzheimer's disease is premature and overlooks significant risks. He calls for more rigorous evidence before widespread use.